ACTU ACTUATE THERAPEUTICS, INC.
Nasdaq · SEC CIK 1652935 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $1.62M 1 sales by 1 insiders
- Filings on record
- 38 since 2024-08-14, latest 2026-08-14 17:00
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| THOMSON TODD S | Dir, 10% | — | $1.62M |
| SCHMITT DANIEL M | Pres, CEO, Dir | — | — |
Transactions 26
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-14 17:00 | 2026-08-14 | ACTU | SCHMITT DANIEL M | Pres, CEO, Dir | M - OptEx | $0.00 | +272.1K | 422.2K | +181% | $0 |
| D | 2026-08-14 17:00 | 2026-08-14 | ACTU | SCHMITT DANIEL M | Pres, CEO, Dir | F - Tax | $1.01 | -120.5K | 301.7K | -29% | -$121.7K |
| D | 2026-02-13 | 2026-02-13 | ACTU | SCHMITT DANIEL M | Pres, CEO, Dir | F - Tax | $4.33 | -121.9K | 150.2K | -45% | -$527.7K |
| D | 2026-02-13 | 2026-02-13 | ACTU | SCHMITT DANIEL M | Pres, CEO, Dir | M - OptEx | $0.00 | +272.1K | 272.1K | New | $0 |
| I | 2026-01-07 | 2026-01-05 | ACTU | THOMSON TODD S | Dir, 10% | S - Sale | $5.80 | -280.0K | 904.8K | -24% | -$1.62M |
| DI | 2025-06-30 | 2025-06-27 | ACTU | BIOS Fund II, LP | Dir, 10% | P - Purchase | $7.00 | +71.4K | 196.4K | +57% | +$500.0K |
| DI | 2025-06-30 | 2025-06-27 | ACTU | BIOS Actuate Co-Invest I, LP | Dir, 10% | P - Purchase | $7.00 | +71.4K | 196.4K | +57% | +$500.0K |
| DI | 2025-06-30 | 2025-06-27 | ACTU | Bios Equity COF, LP | Dir, 10% | P - Purchase | $7.00 | +71.4K | 196.4K | +57% | +$500.0K |
| MAI | 2024-08-20 | 2024-08-14 | ACTU | BIOS Fund II, LP | Dir, 10% | S - Sale | $8.00 | -25.0K | 980.4K | -2% | -$200.0K |
| MAI | 2024-08-20 | 2024-08-14 | ACTU | Bios Clinical Opportunity Fund, LP | Dir, 10% | S - Sale | $8.00 | -25.0K | 300.1K | -8% | -$200.0K |
| MAI | 2024-08-20 | 2024-08-14 | ACTU | BIOS Capital Management, LP | Dir, 10% | S - Sale | $8.00 | -25.0K | 980.4K | -2% | -$200.0K |
| DMI | 2024-08-16 | 2024-08-14 | ACTU | Kairos-Actuate SPV, L.P. | Dir, 1.5% Owner | C - Cnv Deriv | — | +2.58M | 321.8K | New | — |
| DI | 2024-08-16 | 2024-08-14 | ACTU | Kairos-Actuate SPV, L.P. | Dir, 1.5% Owner | X - OptEx | $5.27 | +28.5K | 1.20M | +2% | +$150.0K |
| DI | 2024-08-16 | 2024-08-14 | ACTU | Kairos-Actuate SPV, L.P. | Dir, 1.5% Owner | S - Sale+OE | $8.00 | -18.8K | 1.18M | -2% | -$150.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BP Directors, LP | Dir, 10% | C - Cnv Deriv | — | +9.38M | 573.4K | New | — |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BP Directors, LP | Dir, 10% | X - OptEx | $5.27 | +38.0K | 133.6K | +40% | +$200.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BP Directors, LP | Dir, 10% | S - Sale+OE | $9.00 | -25.0K | 131.2K | -16% | -$225.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BP Directors, LP | Dir, 10% | P - Purchase | $8.00 | +500.0K | 125.0K | New | +$4.00M |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Fund II QP, LP | Dir, 10% | C - Cnv Deriv | — | +9.38M | 61.9K | New | — |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Fund II QP, LP | Dir, 10% | X - OptEx | $5.27 | +38.0K | 133.6K | +40% | +$200.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Fund II QP, LP | Dir, 10% | S - Sale+OE | $9.00 | -25.0K | 131.2K | -16% | -$225.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Fund II QP, LP | Dir, 10% | P - Purchase | $8.00 | +500.0K | 125.0K | New | +$4.00M |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Equity Partners III, LP | Dir, 10% | C - Cnv Deriv | — | +9.38M | 573.4K | New | — |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Equity Partners III, LP | Dir, 10% | S - Sale+OE | $9.00 | -25.0K | 980.4K | -2% | -$225.0K |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Equity Partners III, LP | Dir, 10% | P - Purchase | $8.00 | +500.0K | 1.26M | +66% | +$4.00M |
| DMI | 2024-08-14 | 2024-08-14 | ACTU | BIOS Equity Partners III, LP | Dir, 10% | X - OptEx | $5.27 | +38.0K | 133.6K | +40% | +$200.0K |
Purchase Sale Sale after option exercise All abbreviations